Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Perris

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Leukemia|June 29, 2023
MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemiaLaura Mazzera, Manuela Abeltino, Guerino Lombardi, et al.
Leukemia|June 24, 2026
Retraction Note: MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemiaLaura Mazzera, Manuela Abeltino, Guerino Lombardi, et al.
Journal of Personalized Medicine|May 28, 2022
Validation of a Novel Three-Dimensional (<i>3D Fusion</i>) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 StudyMatteo Brunelli, Guido Martignoni, Giorgio Malpeli, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Leukemia|June 29, 2023
MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemiaLaura Mazzera, Manuela Abeltino, Guerino Lombardi, et al.
Leukemia|June 24, 2026
Retraction Note: MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemiaLaura Mazzera, Manuela Abeltino, Guerino Lombardi, et al.
Journal of Personalized Medicine|May 28, 2022
Validation of a Novel Three-Dimensional (<i>3D Fusion</i>) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 StudyMatteo Brunelli, Guido Martignoni, Giorgio Malpeli, et al.
Pageof 7